

BLONDER TONGUE LABORATORIES INC  
Form 8-K  
February 14, 2019

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**Current Report Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): February 14, 2019**

**Blonder Tongue Laboratories, Inc.**

**(Exact Name of registrant as specified in its charter)**

Delaware

1-14120

52-1611421

**(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)**

**One Jake Brown Road, Old Bridge, New Jersey 08857**

**(Address of principal executive offices) (Zip Code)**

**Registrant's telephone number, including area code: (732) 679-4000**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Edgar Filing: BLONDER TONGUE LABORATORIES INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On February 14, 2019, the Compensation Committee (the “Committee”) of the Board of Directors of Blonder Tongue Laboratories, Inc. (the “Company”) set the base compensation of Robert J. Pallé, the Company’s President and Chief Executive Officer, at \$328,000 per year, retroactive to January 1, 2019. In addition, the Committee determined that the previously-reported bonus payment to Mr. Pallé, which was to be paid in connection with the completion of the sale of the Company’s Old Bridge Facility, was calculated incorrectly. The bonus payable to Mr. Pallé is \$185,000, not the previously-reported amount of \$165,000.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BLONDER  
TONGUE  
LABORATORIES,  
INC.

By: */s/ Eric Skolnik*  
Eric Skolnik  
Senior Vice  
President and Chief  
Financial Officer

Date: February 14, 2019